default author photo

Martin Meyer

Miltenyi Biotec B.V. & Co. KG

Bergisch Gladbach

51429

Germany

SCHOLARLY PAPERS

1

DOWNLOADS

37

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by Omicron

Number of pages: 49 Posted: 17 Aug 2022
German Center for Neurodegenerative Diseases (DZNE), German Center for Neurodegenerative Diseases (DZNE), Miltenyi Biotec B.V. & Co. KG, Berlin Institute of Health - Institute of Virology, German Center for Neurodegenerative Diseases (DZNE), Free University of Berlin (FUB) - Institut für Virologie, Miltenyi Biotec B.V. & Co. KG, Miltenyi Biotec B.V. & Co. KG, Miltenyi Biotec B.V. & Co. KG, Miltenyi Biotec B.V. & Co. KG, Miltenyi Biotec B.V. & Co. KG, German Center for Neurodegenerative Diseases (DZNE), Charité - Universitätsmedizin Berlin - Institute of Virology, Charité - Universitätsmedizin Berlin - Institute of Virology, Christian Albrechts-University of Kiel - Institute for Infection Medicine, Christian Albrechts-University of Kiel - Institute for Infection Medicine, IDEXX Laboratories, Free University of Berlin (FUB) - Institut für Virologie, Free University of Berlin (FUB) - Institut für Virologie, Free University of Berlin (FUB) - Institut für Virologie, German Center for Neurodegenerative Diseases (DZNE), Charité - Universitätsmedizin Berlin - Department of Infectious Diseases and Respiratory Medicine, Miltenyi Biotec B.V. & Co. KG, Charité - Universitätsmedizin Berlin - Institute of Virology and German Center for Neurodegenerative Diseases (DZNE)
Downloads 37 (1,222,651)

Abstract:

Loading...

COVID-19, SARS-CoV-2, therapeutic antibody, variant of concern, potency breadth, hamster model, human membrane protein library, human tissue cross-reactivity study, Omicron, N440K